New drug ZGGS15 tested in patients with advanced cancers
NCT ID NCT05864573
First seen Jan 11, 2026 · Last updated Jun 22, 2026 · Updated 26 times
Summary
This early-stage trial tested a new biologic drug called ZGGS15 in 22 adults with advanced solid tumors who had no standard treatment options left. The main goals were to check safety, find the right dose, and look for early signs that the drug might control tumor growth. Participants received the drug by IV infusion once every three weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ZGGS15 (a biologic drug given by IV infusion)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 22 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.